German generic drugmaker Stada has agreed to a shareholder vote on proposed board changes after an activist investor had asked for a thorough overhaul, the company said on Friday.
Active Ownership Capital will now seek to replace three instead of five of Stada’s nine supervisory board members at its annual general meeting on June 9, and it is no longer asking for the removal of board Chairman Martin Abend.
Stada said in a statement it was agreeing to the compromise to avoid a pricey legal battle as well as the need to call an extraordinary meeting of shareholders.
Shares in Stada have surged about 11 percent this month on speculation that Active Ownership’s campaign could lead to the sale or break up of the company.
The Luxembourg-based investor, which has a 5 percent stake in the company, has said its push for a shareholder vote on the supervisory board is to add international healthcare expertise to help Stada realise its potential.
Active Ownership wants Klaus-Joachim Krauth, the former finance chief of Hexal and Athos; Ulrich Wandschneider, who until recently was chief executive of hospitals chain Asklepios Kliniken; and Active Ownership founding partner Klaus Roehrig on the supervisory board.
They would replace Eckhard Brueggemann, Arnold Hertzsch and Constantin Meyer.
By Arno Schuetze, Alexander Huebner and Maria Sheahan
Source: Reuters
Hybrid closed-loop systems rely on an algorithm to first analyze real-time blood sugar readings from a continuous glucose monitor, then use the results to adjust an insulin pump’s output as needed throughout the day. In this case, the algorithm was developed by Diabeloop, the CGM is a Dexcom G6 sensor, and the insulin pump comes from ViCentra.
Boehringer Ingelheim has acquired bacterial cancer therapy company T3 Pharmaceuticals in a deal that could be worth up to 450 million Swiss francs ($508 million). The addition of Allschwil, Switzerland-based T3 will “significantly expand” the German drugmaker’s immuno-oncology pipeline and aligns with some of the company’s existing R&D programs.
EuroAPI has completed the acquisition of BianoGMP, a contract development and manufacturing organization (CDMO) specializing in oligonucleotides. The acquisition, announced in August, further differentiates its value proposition to support a broader client base across the whole oligonucleotide development continuum, from research to commercialization, EuroAPI said.
